Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

271 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long Terms Follow-Up of the Randomized MetaspHER Study Comparing Intravenous Versus Subcutaneous Trastuzumab in Patients' With HER2-Positive Metastatic Breast Cancer.
Pivot X, Spano JP, Espie M, Jouannaud C, Pottier V, Moreau L, Extra JM, Lortholary A, Rivera P, Spaeth D, Mouri Z, Tariket F, Dupin J, Berthois A, Ionescu-Goga M, Ferhat A, Cottu P, Gligorov J. Pivot X, et al. Among authors: spano jp. Clin Breast Cancer. 2023 Oct;23(7):e412-e419. doi: 10.1016/j.clbc.2023.06.007. Epub 2023 Jun 20. Clin Breast Cancer. 2023. PMID: 37423801
Recommandations francophones pour la pratique clinique concernant la prise en charge des cancers du sein de Saint-Paul-de-Vence 2022-2023.
Gligorov J, Benderra MA, Barthere X, de Forceville L, Antoine EC, Cottu PH, Delaloge S, Pierga JY, Belkacemi Y, Houvenaegel G, Pujol P, Rivera S, Spielmann M, Penault-Llorca F, Namer M; et l'ensemble des experts des votes des RPC Saint-Paul 2022-2023. Gligorov J, et al. Bull Cancer. 2023 Nov;110(10S):10S1-10S43. doi: 10.1016/S0007-4551(23)00473-3. Bull Cancer. 2023. PMID: 38061827
FOLFIRI in advanced platinum-resistant/refractory small-cell lung cancer: a retrospective study.
Roussel-Simonin C, Gougis P, Lassoued D, Vozy A, Veyri M, Morardet L, Wassermann J, Foka Tichoue H, Jaffrelot L, Hassani L, Perrier A, Bergeret S, Taillade L, Spano JP, Campedel L, Abbar B. Roussel-Simonin C, et al. Among authors: spano jp. Acta Oncol. 2023 Jun;62(6):579-586. doi: 10.1080/0284186X.2023.2216339. Epub 2023 Jun 5. Acta Oncol. 2023. PMID: 37276270
An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas.
Lu X, Vano Y, Helleux A, Su X, Lindner V, Davidson G, Mouawad R, Spano JP, Rouprêt M, Elaidi R, Compérat E, Verkarre V, Sun C, Chevreau C, Bennamoun M, Lang H, Tricard T, Cheng W, Xu L, Davidson I, Yan F, Fridman WH, Sautes-Fridman C, Oudard S, Malouf GG. Lu X, et al. Among authors: spano jp. Clin Cancer Res. 2023 Apr 3;29(7):1279-1291. doi: 10.1158/1078-0432.CCR-22-2133. Clin Cancer Res. 2023. PMID: 36374555
Immune Checkpoint Inhibitor Use During Pregnancy and Outcomes in Pregnant Individuals and Newborns.
Gougis P, Hamy AS, Jochum F, Bihan K, Carbonnel M, Salem JE, Dumas E, Kabirian R, Grandal B, Barraud S, Coussy F, Hotton J, Savarino R, Marabelle A, Cadranel J, Spano JP, Laas E, Reyal F, Abbar B. Gougis P, et al. Among authors: spano jp. JAMA Netw Open. 2024 Apr 1;7(4):e245625. doi: 10.1001/jamanetworkopen.2024.5625. JAMA Netw Open. 2024. PMID: 38630478 Free PMC article.
Burden of grade 3 or 4 liver injury associated with immune checkpoint inhibitors.
Parlati L, Sakka M, Retbi A, Bouam S, Hassani L, Meritet JF, Rufat P, Bonnefont-Rousselot D, Batista R, Terris B, Bellanger A, Thabut D, Vozy A, Spano JP, Coriat R, Goldwasser F, Aractingi S, Sogni P, Pol S, Mallet V; CERTIM Research Group; DEMOSTHENES Research Group. Parlati L, et al. Among authors: spano jp. JHEP Rep. 2023 Aug 12;5(12):100880. doi: 10.1016/j.jhepr.2023.100880. eCollection 2023 Dec. JHEP Rep. 2023. PMID: 38074948 Free PMC article.
Initial experience, feasibility, and technical development with an electromagnetic navigation assistance in percutaneous pelvic bone cementoplasty: retrospective analysis.
Boeken T, Pouliquen G, Premat K, Benac B, Shotar E, Cormier É, Talbi A, Bonaccorsi R, Morardet L, Morel V, Spano JP, Pascal-Mousselard H, Chiras J, Clarençon F. Boeken T, et al. Among authors: spano jp. Eur Radiol. 2023 Apr;33(4):2605-2611. doi: 10.1007/s00330-022-09252-x. Epub 2022 Nov 15. Eur Radiol. 2023. PMID: 36378253
Treatments During Pregnancy Targeting ERBB2 and Outcomes of Pregnant Individuals and Newborns.
Gougis P, Grandal B, Jochum F, Bihan K, Coussy F, Barraud S, Asselain B, Dumas E, Sebbag C, Hotton J, Spaggiari E, Pierga JY, Savarino R, Laas E, Spano JP, Reyal F, Hamy AS. Gougis P, et al. Among authors: spano jp. JAMA Netw Open. 2023 Oct 2;6(10):e2339934. doi: 10.1001/jamanetworkopen.2023.39934. JAMA Netw Open. 2023. PMID: 37883083 Free PMC article.
First-in-human study of an OX40 (ivuxolimab) and 4-1BB (utomilumab) agonistic antibody combination in patients with advanced solid tumors.
Hamid O, Chiappori AA, Thompson JA, Doi T, Hu-Lieskovan S, Eskens FALM, Ros W, Diab A, Spano JP, Rizvi NA, Wasser JS, Angevin E, Ott PA, Forgie A, Yang W, Guo C, Chou J, El-Khoueiry AB. Hamid O, et al. Among authors: spano jp. J Immunother Cancer. 2022 Oct;10(10):e005471. doi: 10.1136/jitc-2022-005471. J Immunother Cancer. 2022. PMID: 36302562 Free PMC article. Clinical Trial.
271 results